Business
EPISTEM RECEIVES PRESTIGIOUS FP7 GRANT AWARD
EPISTEM RECEIVES PRESTIGIOUS FP7 GRANT AWARD.
About this update from Genedrive Plc
[{"type":"text","content":"\n \nRNS Number : 1942L Epistem Holdings plc 08 August 2013 \n \n\n \n \nCompany Epistem Plc\nTIDM EHP.L (AIM)\nHeadline EPISTEM RECEIVES A PRESTIGIOUS FP7 GRANT AWARD FOR THE DEVELOPMENT OF POINT OF CARE HEPATITIS C ASSAYS\nReleased 8th August 2013 (UK:7.00am) \nNumber \n \nEpistem Plc\n(\"Epistem\" or \"the Company\")\nEPISTEM RECEIVES A PRESTIGIOUS FP7 GRANT AWARD FOR THE DEVELOPMENT OF POINT OF CARE HEPATITIS C ASSAYS \nMANCHESTER, UNITED KINGDOM - Epistem plc (LSE:EHP), the UK biotechnology and personalised medicine company, is pleased to announce that it has been awarded funding of €1.5 million over a three year period by the European Commission's 7th Framework Programme as part of a €6.0 million consortium project (Grant n° 601851) for the development of Point of Care Hepatitis C assays. The PoC-HCV consortium additionally consists of the coordinator Inserm (Institut Pasteur) (France), Inserm Transfert (France), Qlucore (Sweden) and Biosurfit (Portugal).\nThe primary objective of the PoC-HCV consortium is to provide PoC diagnostic and predictive tests that enable tangible improvements in the health and quality of life of chronic Hepatitis C patients, while simultaneously helping to manage the rising cost of medical treatment. It is an approach that capitalises on the consortiums combined expertise spanning leading edge miniaturised molecular testing, lab-on-a-chip systems and treatment algorithm design. These enabling technologies will permit the development and delivery of the first integrated genetic and protein biomarker tests, applied here to Hepatitis C disease for: (i) making the decision to treat; (ii) selection of therapy; (iii) response-guided monitoring; and (iv) clinical research practices.\nEpistem will develop a number of tests on Genedrive® our hand-held CE-IVD marked PCR platform that provides rapid genotype tests results. The assays ...